Microbiological Profile of Post-cataract Surgery Endophthalmitis with Usage of Prophylactic Intracameral Moxifloxacin

Dropless Cataract Surgery: A Review of the Literature

Cataract surgery is one of the most performed surgeries worldwide, often necessitating postoperative eye drops to manage infection, inflammation, and pain. However, complex regimens, patient adherence challenges, and environmental concerns have led to growing interest in "dropless" cataract surgery, which eliminates or reduces the need for postoperative drops by delivering medications intraoperatively through injections or drug-eluting implants. This review provides an overview of dropless cataract surgery, focusing on common medications used including antibiotics, steroids, nonsteroidal anti-inflammatory drugs, and intraocular pressure medications. Intracameral antibiotic use has become widespread, with strong evidence showing that it effectively reduces the risk of postoperative endophthalmitis without the need for additional topical antibiotics. Steroids, typically delivered through subconjunctival injections or sustained-release implants, show promise in safely and effectively controlling inflammation, though further research is needed to validate fully dropless approaches. Nonsteroidal anti-inflammatory drugs and intraocular pressure medications are less frequently included in dropless regimens, with mixed evidence regarding their impact on long-term outcomes. For patients, dropless cataract surgery can help simplify postoperative care and potentially lower out-of-pocket costs. For health systems, recent analyses suggest dropless surgery could reduce overall costs and decrease environmental waste by reducing consumption of eye drop bottles. Future research should focus on assessing true dropless approaches and optimizing medication delivery. Overall, dropless cataract surgery offers many potential benefits for patients, health systems, and the environment. Additional high-quality evidence substantiating these benefits would help advance its adoption globally.

Intracameral antibiotics during cataract surgery: efficacy, safety, and cost-benefit considerations

PURPOSE OF REVIEW

We summarize evidence-based considerations regarding the use of intracameral antibiotics during cataract surgery.

RECENT FINDINGS

The use of intraoperative intracameral antibiotics reduced the incidence of postcataract surgery endophthalmitis 3.5-fold, with an odds ratio ranging from 0.14 to 0.19. A survey of the American Society of Cataract and Refractive Surgery showed usage of intracameral injections of antibiotics increased by 16% in the United States between 2014 and 2021. The frequency of vancomycin usage has sharply dropped to 6%, while moxifloxacin is now the dominant choice at 83% among respondents. One analysis showed that 2500 patients need to be treated with intracameral antibiotics to prevent one case of endophthalmitis. A 500 μg intracameral moxifloxacin at $22 dollars per dose is cost-effective, including for patients with posterior capsular rupture (PCR).

SUMMARY

Studies substantiate the safety and efficacy of intracameral antibiotics for endophthalmitis prophylaxis. Intracameral moxifloxacin and cefuroxime are the most common choices. While vancomycin shows potential for efficacy, further studies evaluating clinical outcomes are needed. Adverse events are rare and commonly due to errors in preparation. Topical antibiotics do not provide additional prophylactic benefits to intracameral regimens. Intracameral antibiotics given alone are cost-effective.